Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026
Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026
Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026
Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026
Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Company Deals

Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility

Fineline Cube May 13, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...

Company Drug

Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025

Fineline Cube May 13, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...

Company

Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal

Fineline Cube May 13, 2025

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...

Company Deals Drug

Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007

Fineline Cube May 13, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...

Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Company Drug

BeiGene’s Sonrotoclax Gains NMPA Priority Review for MCL Treatment

Fineline Cube May 13, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Medical Device

United Imaging Healthcare Gains FDA Approval for uAngio AVIVA Interventional X-ray System

Fineline Cube May 13, 2025

China-based United Imaging Healthcare (UIH, SHA: 688271) announced that it has received marketing approval from...

Policy / Regulatory

Trump Executive Order Seeks to Align US Prescription Drug Prices with Global Standards

Fineline Cube May 13, 2025

U.S. President Donald J. Trump has signed an executive order aimed at aligning prescription drug...

Company Drug

Fosun Pharma’s FCN-159 Granted Breakthrough Therapy Designation for Pediatric LCH

Fineline Cube May 13, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its novel small-molecule...

Company Drug

Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections

Fineline Cube May 13, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...

Company Deals

Roche Invests $550 Million in Indianapolis Diagnostics Facility for CGM Systems

Fineline Cube May 13, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced plans to invest up to USD 550...

Company Drug

RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints

Fineline Cube May 13, 2025

China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...

Company Deals

Eastenova Biotechnology Makes Hong Kong IPO Debut With Regenerative Medicine Focus

Fineline Cube May 13, 2025

China-based Eastenova (Chengdu) Biotechnology Co., Ltd. this week made an initial public offering (IPO) to...

Company Drug

AstraZeneca’s Trixeo Aerosphere Wins UK Approval for COPD

Fineline Cube May 13, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced this week that it has received marketing...

Company Drug

Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial

Fineline Cube May 13, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

Fineline Cube May 12, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...

Posts pagination

1 … 113 114 115 … 615

Recent updates

  • Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
  • Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
  • Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
  • Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
  • Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.